Eligibility Details:  
        Inclusion Criteria:
          1. Female patient, aged 18 years or older at the time of enrollment,
          2. primary symptoms of SUI, as confirmed by patient medical history and clinical
             symptoms, including a focused incontinence evaluation; for a duration of at least 3
             months (patient can be rescreened after this time interval has passed).
          3. The patient agrees to no new parallel treatment for SUI during the treatment period
             and the 6 months following it.
          4. objective proof of SUI: Observation of urine leakage by cough and valsalva (positive
             stress test) at a bladder volume of ≤ 300cc
          5. Bladder capacity ≥200cc
          6. Post void residual ≤100cc with Stage I or lower pelvic organ prolapse
        Exclusion Criteria:
          1. Patient is pregnant, lactating, or plans to become pregnant during the course of the
             Study; or Patient is <12 months post partum
          2. Patient has other predominant type of UI (eg Urgency UI, overflow UI, fistula)
          3. Patient has a vaginal condition that does not allow proper vaginal placement of the
             laser probe in its protective speculum
          4. Current chemo/ radiotherapy; history of pelvic radiation
          5. Systemic diseases known to affect bladder function (eg Parkinson's disease, multiple
             sclerosis, spina bifida, spinal cord injury)
          6. Current or history of urethral diverticulum, prior augmentation cystoplasty, implanted
             nerve stimulators for bladder symptoms
          7. History of synthetic sling
          8. Pelvic surgery < 3 months
          9. Current evaluation or treatment for chronic pelvic pain
         10. Patient has pelvic organ/ vaginal prolapse extending to or out of the vaginal opening
         11. Participation in another treatment intervention that might interfere with the results
             of this trial
         12. Patient has a medical condition or disorder that may limit life expectancy or that may
             cause non-compliance with the protocol (e.g. unable to perform self-evaluations and/or
             accurately report medical history, urinary symptoms, and/or data).
         13. Patient has ambulatory 24 hour pad test, where the increased pad weight is < 3 grams.
         14. Patient is non-ambulatory (ambulatory with assistive devices allowed)